Treatment (which is based on supportive care) is as follows: Pyrimethamine-based maintenance therapy is often used to treat Toxoplasmic<unk>  (TE), which is caused by Toxoplasma gondii and can be life-threatening for people with weak immune systems. The use of highly active antiretroviral therapy (HAART), in conjunction with the established pyrimethamine-based maintenance therapy, decreases the chance of relapse in patients with HIV and TE from approximately 18% to 11%. This is a significant difference as relapse may impact the severity and prognosis of disease and result in an increase in healthcare expenditure. The effectiveness of intravenous immunoglobulin for the management of childhood<unk>  is unclear. Systematic reviews have been unable to draw firm conclusions because of a lack of randomised double-blind studies with sufficient numbers of patients and sufficient follow-up. There is the possibility of a benefit of intravenous immunoglobulin for some forms of childhood<unk>  on some indicators such as length of hospital stay, time to stop spasms, time to regain consciousness, and time to resolution of neuropathic symptoms and fever. Intravenous immunoglobulin for Japanese<unk>  appeared to have no benefit when compared with placebo (pretend) treatment.
Encephalitis
Meningitis
Creutzfeldt–Jakob disease  Creutzfeldt–Jakob disease  1
Meningoencephalitis
Encephalomyelitis
Cerebritis
Seroma
Meninges